Wednesday, October 25, 2017 10:15 PM ET
Aimmune Therapeutics (AIMT) sees Significant Insider Selling Continuing
There was a substantial sale of shares of Aimmune Therapeutics by an insider today, as indicated in a form 4 document filed with the SEC. One insider — Dr Stephen George Dilly, Director and Officer — disposed of 100,000 shares in the company having a market value of approximately $3,354,538. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the sale of 150,000 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 250,000 shares and have averaged 125,000 shares per transaction over this time period.
Insiders at Aimmune Therapeutics have a higher number of buy/sell trades than the 19-peer company average over the last 90-day period. The Specialty & Advanced Pharmaceuticals peer group saw 25 buy/sell trades during this period for an average of 1.3 transactions per company. The number of shares per buy/sell trade for Aimmune Therapeutics insiders was also higher. Within the peer group there were 621,842 shares purchased and 187,563 shares sold with company insiders purchasing 22,857 shares on average.
The data obtained in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.